Status:
COMPLETED
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Lead Sponsor:
John P. Fruehauf
Collaborating Sponsors:
Bayer
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in subjects who have metastatic melanoma which has advanced beyond the point at which local therapies such as surgery or ra...
Detailed Description
Annually in the U.S. there is an estimated 40,000 new cases of malignant melanoma and 7000 deaths. This disease is becoming more common with its incidence increasing at a more rapid rate in the past d...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18
- Karnofsky Performance Status (KFS) of greater than or equal to 70
- Laboratory values (performed in 14 days, inclusive prior to study drug administration):
- Absolute neutrophil count (ANC) \>1500/mm3
- Platelet count \>100,000/mm3
- Hemoglobin \> 10 g/dl
- Blood urea nitrogen (BUN) and serum creatinine \< 0.5 times the upper limit of laboratory normal
- Total and direct bilirubin \< 1.5 times the upper limit of laboratory normal
- Serum glutamic-oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase(SGPT) \< 3 times the upper limit of laboratory normal
- Alkaline phosphatase \< 3 times upper limit of laboratory normal
- Life expectancy of greater than 12 weeks
- Written informed consent
Exclusion
- No recovery from all active toxicities of prior therapies
- Surgery within 1 week prior to study drug administration, providing acute surgical toxicity is resolved
- Subjects within acute infection treated with intravenous antibiotics
- Frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)
- Concurrent malignancies at other sites with the exception of surgically cured carcinoma in situ (CIS ) of the cervix, basal or squamous cell carcinoma of the skin, and prior malignancies which have not required anit-tumor treatment within the preceding 24 months
- Known HIV-positivity or AIDS-related illness
- Women of childbearing potential who are not using an effective method of contraception (eligible patients must have a negative urine pregnancy test 24 hours prior to administration of study drug and be practicing medically approved contraceptive precautions)
- Men who do not use an effective method of contraception.
- Chemotherapy within four weeks prior to study drug administration or biologic therapy/immunotherapy within two weeks prior to study drug administration
- Completion of radiation therapy, interstitial brachytherapy, or radiosurgery within 4 weeks prior to study drug administration (patients with brain metastases from melanoma must have completed radiotherapy to the brain at least 3 weeks before study commences)
- Bone metastases as sole reason for Stage IV disease
- Karnofsky Performance Status of less than or equal to 60
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00256282
Start Date
April 1 2003
End Date
August 1 2012
Last Update
May 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868